NO331700B1 - Anvendelse av preparat for fremstilling av medikament for fjerning av fibrinbundet blodpropp fra kateter, og multiseksjonsforpakning omfattende preparatet - Google Patents

Anvendelse av preparat for fremstilling av medikament for fjerning av fibrinbundet blodpropp fra kateter, og multiseksjonsforpakning omfattende preparatet Download PDF

Info

Publication number: NO331700B1
Authority: NO; Norway
Prior art keywords: catheter; plasminogen activator; sample; preparation; use according
Prior art date: 2001-11-26

Application number

NO20042693A

Other languages

English (en)

Norwegian (no)

Other versions

NO20042693L (no

Inventor

Charles P Semba

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-26

Filing date

2004-06-25

Publication date

2012-02-27

2004-06-25 Application filed by Genentech Inc filed Critical Genentech Inc

2004-08-25 Publication of NO20042693L publication Critical patent/NO20042693L/no

2012-02-27 Publication of NO331700B1 publication Critical patent/NO331700B1/no

Links

102000009123 Fibrin Human genes 0.000 title claims abstract description 25
108010073385 Fibrin Proteins 0.000 title claims abstract description 25
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims abstract description 25
229950003499 fibrin Drugs 0.000 title claims abstract description 25
208000007536 Thrombosis Diseases 0.000 title claims abstract description 17
239000003814 drug Substances 0.000 title claims description 13
238000004519 manufacturing process Methods 0.000 title claims description 4
238000004806 packaging method and process Methods 0.000 title claims 11
239000000203 mixture Substances 0.000 title description 21
238000002360 preparation method Methods 0.000 claims abstract description 54
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 44
102000001938 Plasminogen Activators Human genes 0.000 claims abstract description 28
108010001014 Plasminogen Activators Proteins 0.000 claims abstract description 28
229940127126 plasminogen activator Drugs 0.000 claims abstract description 28
230000003385 bacteriostatic effect Effects 0.000 claims abstract description 17
239000002738 chelating agent Substances 0.000 claims abstract description 16
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 60
239000000243 solution Substances 0.000 claims description 47
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
108010039185 Tenecteplase Proteins 0.000 claims description 24
229960000216 tenecteplase Drugs 0.000 claims description 24
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 21
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 21
235000019445 benzyl alcohol Nutrition 0.000 claims description 20
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 15
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 15
238000001990 intravenous administration Methods 0.000 claims description 13
229960005356 urokinase Drugs 0.000 claims description 13
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 7
239000008228 bacteriostatic water for injection Substances 0.000 claims description 5
229960002917 reteplase Drugs 0.000 claims description 4
108010051412 reteplase Proteins 0.000 claims description 4
229960000187 tissue plasminogen activator Drugs 0.000 claims description 4
108050006955 Tissue-type plasminogen activator Proteins 0.000 claims 5
102100033571 Tissue-type plasminogen activator Human genes 0.000 claims 5
239000000523 sample Substances 0.000 description 68
238000000034 method Methods 0.000 description 57
238000012360 testing method Methods 0.000 description 56
230000009467 reduction Effects 0.000 description 31
230000000845 anti-microbial effect Effects 0.000 description 28
238000002835 absorbance Methods 0.000 description 25
239000012895 dilution Substances 0.000 description 21
238000010790 dilution Methods 0.000 description 21
235000018102 proteins Nutrition 0.000 description 19
102000004169 proteins and genes Human genes 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 19
230000000694 effects Effects 0.000 description 18
208000015181 infectious disease Diseases 0.000 description 18
229960003318 alteplase Drugs 0.000 description 17
239000000463 material Substances 0.000 description 17
238000004458 analytical method Methods 0.000 description 16
239000003146 anticoagulant agent Substances 0.000 description 16
238000011010 flushing procedure Methods 0.000 description 15
239000004599 antimicrobial Substances 0.000 description 14
238000003860 storage Methods 0.000 description 14
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 13
229960002897 heparin Drugs 0.000 description 13
229920000669 heparin Polymers 0.000 description 13
239000003153 chemical reaction reagent Substances 0.000 description 12
239000003085 diluting agent Substances 0.000 description 12
238000003556 assay Methods 0.000 description 11
239000003527 fibrinolytic agent Substances 0.000 description 11
239000003755 preservative agent Substances 0.000 description 11
102000013566 Plasminogen Human genes 0.000 description 10
108010051456 Plasminogen Proteins 0.000 description 10
238000011534 incubation Methods 0.000 description 10
230000002335 preservative effect Effects 0.000 description 10
230000002792 vascular Effects 0.000 description 10
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
229940127219 anticoagulant drug Drugs 0.000 description 9
239000011248 coating agent Substances 0.000 description 9
238000000576 coating method Methods 0.000 description 9
230000009089 cytolysis Effects 0.000 description 9
229940079593 drug Drugs 0.000 description 9
239000012460 protein solution Substances 0.000 description 9
241000894006 Bacteria Species 0.000 description 8
102000008946 Fibrinogen Human genes 0.000 description 8
108010049003 Fibrinogen Proteins 0.000 description 8
230000008859 change Effects 0.000 description 8
229940012952 fibrinogen Drugs 0.000 description 8
230000003480 fibrinolytic effect Effects 0.000 description 8
239000011521 glass Substances 0.000 description 8
238000001631 haemodialysis Methods 0.000 description 8
230000000322 hemodialysis Effects 0.000 description 8
244000005700 microbiome Species 0.000 description 8
229940012957 plasmin Drugs 0.000 description 8
240000004808 Saccharomyces cerevisiae Species 0.000 description 7
239000003242 anti bacterial agent Substances 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 7
239000002245 particle Substances 0.000 description 7
230000002265 prevention Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
108090000190 Thrombin Proteins 0.000 description 6
230000003115 biocidal effect Effects 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
239000000645 desinfectant Substances 0.000 description 6
238000011081 inoculation Methods 0.000 description 6
239000002054 inoculum Substances 0.000 description 6
229960004023 minocycline Drugs 0.000 description 6
239000000178 monomer Substances 0.000 description 6
239000013642 negative control Substances 0.000 description 6
239000008223 sterile water Substances 0.000 description 6
229960004072 thrombin Drugs 0.000 description 6
108010031891 KHRR 296-299 AAAA T103N Proteins 0.000 description 5
239000004793 Polystyrene Substances 0.000 description 5
229960005475 antiinfective agent Drugs 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000007423 decrease Effects 0.000 description 5
238000000502 dialysis Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000005259 measurement Methods 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920001296 polysiloxane Polymers 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
229920002223 polystyrene Polymers 0.000 description 5
239000012925 reference material Substances 0.000 description 5
239000012898 sample dilution Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000011282 treatment Methods 0.000 description 5
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 4
239000012131 assay buffer Substances 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229960003260 chlorhexidine Drugs 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000012488 sample solution Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
241000222120 Candida <Saccharomycetales> Species 0.000 description 3
241000721047 Danaus plexippus Species 0.000 description 3
206010064687 Device related infection Diseases 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 3
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
239000008272 agar Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
229960004676 antithrombotic agent Drugs 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
239000012470 diluted sample Substances 0.000 description 3
229950007919 egtazic acid Drugs 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000012417 linear regression Methods 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
229920002635 polyurethane Polymers 0.000 description 3
239000004814 polyurethane Substances 0.000 description 3
229910000162 sodium phosphate Inorganic materials 0.000 description 3
239000008227 sterile water for injection Substances 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
229960000103 thrombolytic agent Drugs 0.000 description 3
229940113038 tnkase Drugs 0.000 description 3
238000011179 visual inspection Methods 0.000 description 3
239000008215 water for injection Substances 0.000 description 3
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 2
RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
208000032840 Catheter-Related Infections Diseases 0.000 description 2
241000233866 Fungi Species 0.000 description 2
108010015899 Glycopeptides Proteins 0.000 description 2
102000002068 Glycopeptides Human genes 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000012901 Milli-Q water Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
241000295644 Staphylococcaceae Species 0.000 description 2
241000191963 Staphylococcus epidermidis Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
229940099983 activase Drugs 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000002924 anti-infective effect Effects 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
229940127090 anticoagulant agent Drugs 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
208000020832 chronic kidney disease Diseases 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
230000008021 deposition Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
208000028208 end stage renal disease Diseases 0.000 description 2
201000000523 end stage renal failure Diseases 0.000 description 2
-1 for example Polymers 0.000 description 2
239000012634 fragment Substances 0.000 description 2
229940006607 hirudin Drugs 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
244000052769 pathogen Species 0.000 description 2
229960003330 pentetic acid Drugs 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000012449 sabouraud dextrose agar Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000005070 sampling Methods 0.000 description 2
UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
238000012430 stability testing Methods 0.000 description 2
ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
229960004267 taurolidine Drugs 0.000 description 2
AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 description 2
229950007343 taurultam Drugs 0.000 description 2
235000021476 total parenteral nutrition Nutrition 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
239000006150 trypticase soy agar Substances 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
FFRVQTGCNAGNJO-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-pyrrolidin-1-ylethanamine Chemical compound C=1C=C(F)C=CC=1C(CN)N1CCCC1 FFRVQTGCNAGNJO-UHFFFAOYSA-N 0.000 description 1
MVQXBXLDXSQURK-UHFFFAOYSA-N 2-aminoethanesulfonamide Chemical class NCCS(N)(=O)=O MVQXBXLDXSQURK-UHFFFAOYSA-N 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
208000010470 Ageusia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
241000304886 Bacilli Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
230000010736 Chelating Activity Effects 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
241000306271 Colombian datura virus Species 0.000 description 1
235000019750 Crude protein Nutrition 0.000 description 1
NVTRPRFAWJGJAJ-UHFFFAOYSA-L EDTA monocalcium salt Chemical compound [Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O NVTRPRFAWJGJAJ-UHFFFAOYSA-L 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
229920002306 Glycocalyx Polymers 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
238000013494 PH determination Methods 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
101150035405 SWF1 gene Proteins 0.000 description 1
206010049416 Short-bowel syndrome Diseases 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
206010062546 Thrombosis in device Diseases 0.000 description 1
XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
238000011111 UV-scan method Methods 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000007950 acidosis Effects 0.000 description 1
208000026545 acidosis disease Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
235000019666 ageusia Nutrition 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
229960003093 antiseptics and disinfectants Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229920005549 butyl rubber Polymers 0.000 description 1
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000013522 chelant Substances 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
229960000958 deferoxamine Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
229960001051 dimercaprol Drugs 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
229940095629 edetate calcium disodium Drugs 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229940009626 etidronate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012537 formulation buffer Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
210000004517 glycocalyx Anatomy 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
229940113601 irrigation solution Drugs 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
231100000663 medical toxicology Toxicity 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
238000012009 microbiological test Methods 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000003058 plasma substitute Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000010453 quartz Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229960003600 silver sulfadiazine Drugs 0.000 description 1
238000002791 soaking Methods 0.000 description 1
GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
229960005346 succimer Drugs 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
229940072172 tetracycline antibiotic Drugs 0.000 description 1
229960003766 thrombin (human) Drugs 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960003500 triclosan Drugs 0.000 description 1
WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000002620 vena cava superior Anatomy 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011746 zinc citrate Substances 0.000 description 1
235000006076 zinc citrate Nutrition 0.000 description 1
229940068475 zinc citrate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Enzymes And Modification Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Detergent Compositions (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Apparatus For Disinfection Or Sterilisation (AREA)

NO20042693A 2001-11-26 2004-06-25 Anvendelse av preparat for fremstilling av medikament for fjerning av fibrinbundet blodpropp fra kateter, og multiseksjonsforpakning omfattende preparatet NO331700B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33336901P	2001-11-26	2001-11-26
PCT/US2002/037878 WO2003045466A2 (en)	2001-11-26	2002-11-25	Catheter composition and uses thereof

Publications (2)

Publication Number	Publication Date
NO20042693L NO20042693L (no)	2004-08-25
NO331700B1 true NO331700B1 (no)	2012-02-27

Family

ID=23302492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042693A NO331700B1 (no)	2001-11-26	2004-06-25	Anvendelse av preparat for fremstilling av medikament for fjerning av fibrinbundet blodpropp fra kateter, og multiseksjonsforpakning omfattende preparatet

Country Status (28)

Country	Link
US (3)	US20030206906A1 (es)
EP (1)	EP1455858A4 (es)
JP (1)	JP4458240B2 (es)
KR (2)	KR20040054803A (es)
CN (1)	CN100478027C (es)
AR (1)	AR037437A1 (es)
AU (2)	AU2002365408B2 (es)
BR (1)	BR0215098A (es)
CA (1)	CA2467645C (es)
CO (1)	CO5580795A2 (es)
EA (1)	EA007594B1 (es)
EC (2)	ECSDI045123S (es)
HR (1)	HRP20040502A2 (es)
HU (1)	HUP0600436A3 (es)
IL (2)	IL162083A0 (es)
IS (1)	IS7275A (es)
ME (1)	ME00015B (es)
MX (1)	MXPA04004948A (es)
MY (1)	MY140404A (es)
NO (1)	NO331700B1 (es)
NZ (1)	NZ533029A (es)
PL (1)	PL371760A1 (es)
RS (1)	RS46204A (es)
TW (1)	TWI262794B (es)
UA (1)	UA81235C2 (es)
UY (1)	UY27550A1 (es)
WO (1)	WO2003045466A2 (es)
ZA (1)	ZA200404024B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002365408B2 (en)	2001-11-26	2008-04-24	Genentech, Inc.	Catheter composition and uses thereof
US7128923B2 (en) *	2003-03-31	2006-10-31	Procyte Corporation	Preserved and stable compositions containing peptide copper complexes and method related thereto
CN101563100B (zh) *	2006-08-28	2013-08-07	李季男	用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标
DK2056865T3 (en)	2006-08-28	2014-03-24	Omnio Healer Ab	Hitherto unknown medicinal products for the prevention and treatment of gum disease, improvement of healing of gums in the gums and promotion of dental and oral health
US8916148B2 (en) *	2006-11-07	2014-12-23	Genentech, Inc.	Tissue plasminogen activator variant uses
EP2160152B1 (en)	2007-06-01	2016-07-27	Arrow International, Inc.	Combined fibrinolytic and antimicrobial catheter and uses thereof
EP2711024B1 (en) *	2007-09-07	2019-03-06	United Therapeutics Corporation	Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
US9333280B2 (en)	2009-02-25	2016-05-10	Teleflex Medical Incorporated	Stabilized enzyme compositions
US8545459B2 (en) *	2009-02-25	2013-10-01	Teleflex Medical Incorporated	Stabilized enzyme compositions
US20110213025A1 (en) *	2009-08-10	2011-09-01	Proviflo, Llc	Catheter Lock Solutions Utilizing Tocopherol and Mid-Chain Fatty Acids
CN103083726A (zh) *	2013-03-04	2013-05-08	昆明市第一人民医院	一种肝脏组织脱细胞液
US10456570B2 (en)	2015-06-11	2019-10-29	Proviflo, Llc	Graft-port hemodialysis systems, devices, and methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI831484L (fi)	1982-05-05	1983-11-06	Genentech Inc	Plasminogen aktivator foer maenskovaevnad
US5000185A (en)	1986-02-28	1991-03-19	Cardiovascular Imaging Systems, Inc.	Method for intravascular two-dimensional ultrasonography and recanalization
US5019096A (en) *	1988-02-11	1991-05-28	Trustees Of Columbia University In The City Of New York	Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5270198A (en)	1988-05-20	1993-12-14	Genentech, Inc.	DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8820945D0 (en) *	1988-09-07	1988-10-05	Smith & Nephew	Medical articles
FR2661790B1 (fr) *	1990-05-03	1995-08-25	France Etat	Dispositif d'amplification tres large bande continu-hyperfrequences, notamment realisable en circuit integre.
AU7998091A (en) *	1990-05-17	1991-12-10	Harbor Medical Devices, Inc.	Medical device polymer
US5399158A (en)	1990-05-31	1995-03-21	The United States Of America As Represented By The Secretary Of The Army	Method of lysing thrombi
US5363754A (en) *	1991-09-03	1994-11-15	Grainco Queensland Co-Operative Association Limited	Apparatus for preparing animal feedstuff from cotton seed
JPH05291891A (ja) *	1992-02-14	1993-11-05	Ricoh Co Ltd	一次乱数パルス列発生回路装置
DK0643772T3 (da) *	1992-06-03	1998-02-02	Genentech Inc	Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
US5362754A (en)	1992-11-12	1994-11-08	Univ. Of Tx Md Anderson Cancer Center	M-EDTA pharmaceutical preparations and uses thereof
US5688516A (en) *	1992-11-12	1997-11-18	Board Of Regents, The University Of Texas System	Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
PT730590E (pt)	1993-11-24	2001-05-31	Du Pont Pharm Co	Derivados de isoxazolina e isoxazole como antagonistas dos reciptores do fibrinogenio
US5849736A (en)	1993-11-24	1998-12-15	The Dupont Merck Pharmaceutical Company	Isoxazoline and isoxazole fibrinogen receptor antagonists
US5885967A (en) *	1994-03-04	1999-03-23	Eli Lilly And Company	Antithrombotic agents
US5509896A (en)	1994-09-09	1996-04-23	Coraje, Inc.	Enhancement of thrombolysis with external ultrasound
US5772640A (en) *	1996-01-05	1998-06-30	The Trustees Of Columbia University Of The City Of New York	Triclosan-containing medical devices
CA2178541C (en) *	1995-06-07	2009-11-24	Neal E. Fearnot	Implantable medical device
US5932299A (en) *	1996-04-23	1999-08-03	Katoot; Mohammad W.	Method for modifying the surface of an object
US5840733A (en) *	1996-07-01	1998-11-24	Redcell, Canada, Inc.	Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5837688A (en) *	1996-11-27	1998-11-17	Gelfand; Mathew I.	Use of thrombolytic reagents for prevention of vascular disease
GB9626795D0 (en) *	1996-12-23	1997-02-12	Geistlich Soehne Ag	Combating infection in delivery systems
AU5526098A (en)	1996-12-23	1998-07-17	Biochem Pharma Inc.	Bicyclic thrombin inhibitors
US5981826A (en) *	1997-05-05	1999-11-09	Georgia Tech Research Corporation	Poly(vinyl alcohol) cryogel
JPH10328293A (ja)	1997-06-04	1998-12-15	Unitika Ltd	医療用具及びその製造方法
US6206914B1 (en) *	1998-04-30	2001-03-27	Medtronic, Inc.	Implantable system with drug-eluting cells for on-demand local drug delivery
US6166007A (en) *	1998-07-02	2000-12-26	Sodemann; Klaus	Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
US6174537B1 (en) *	1998-09-25	2001-01-16	Becton, Dickinson And Company	Catheter flush solution and method for its use
EA200100966A1 (ru)	1999-03-11	2002-02-28	Дюпон Фармасьютикалз Компани	ЛЕЧЕНИЕ ТРОМБОЗА КОМБИНИРОВАННЫМ ПРИМЕНЕНИЕМ ИНГИБИТОРА ФАКТОРА Xa И АСПИРИНА, АКТИВАТОРА ТКАНЕВОГО ПЛАЗМИНОГЕНА (TPA), АНТАГОНИСТА GPIIB/IIIA, НИЗКОМОЛЕКУЛЯРНОГО ГЕПАРИНА ИЛИ ГЕПАРИНА
US6346517B1 (en)	1999-03-11	2002-02-12	Bristol-Myers Squibb Pharma Company	Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
CA2302720C (en)	1999-03-29	2009-07-14	Ed Geistlich Sohne Ag Fur Chemische Industrie	Anticoagulant/sterilizing compositions and methods
US6187768B1 (en) *	1999-06-01	2001-02-13	Becton, Dickinson And Company	Kit for flushing medical devices and method of preparation
EP1060747A3 (en) *	1999-06-16	2001-12-05	New York Blood Center, Inc.	Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase
US6592564B2 (en) *	1999-07-23	2003-07-15	Vasca, Inc.	Methods and kits for locking and disinfecting implanted catheters
US6350251B1 (en)	2000-01-18	2002-02-26	Biolink Corporation	Biocidal locks
US20010031981A1 (en)	2000-03-31	2001-10-18	Evans Michael A.	Method and device for locating guidewire and treating chronic total occlusions
ATE394134T1 (de)	2000-05-10	2008-05-15	Ash Access Technology Inc	Kathetersperrlösung mit photo-oxidant
US6772640B1 (en) *	2000-10-10	2004-08-10	Mks Instruments, Inc.	Multi-temperature heater for use with pressure transducers
US20050215978A1 (en)	2001-05-25	2005-09-29	Ash Stephen R	Method of enhancing catheter patency using a citrate salt catheter lock solution
AU2002365408B2 (en)	2001-11-26	2008-04-24	Genentech, Inc.	Catheter composition and uses thereof
US20070014779A1 (en)	2002-11-14	2007-01-18	Genentech, Inc.	Plasminogen activator variant formulations
ES2282529T3 (es)	2003-02-03	2007-10-16	Hans-Dietrich Dr.Techn. Polaschegg	Composicion para la prevencion de una infeccion debida a un dispositi vo permanente.
US7696182B2 (en)	2004-11-02	2010-04-13	Nd Partners, Llc	Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US7749529B2 (en)	2005-02-08	2010-07-06	Ash Access Technology, Inc.	Catheter lock solution comprising citrate and a paraben
US8916148B2 (en)	2006-11-07	2014-12-23	Genentech, Inc.	Tissue plasminogen activator variant uses

2002
- 2002-11-25 AU AU2002365408A patent/AU2002365408B2/en not_active Ceased
- 2002-11-25 US US10/304,666 patent/US20030206906A1/en not_active Abandoned
- 2002-11-25 CN CNB028275578A patent/CN100478027C/zh not_active Expired - Fee Related
- 2002-11-25 EP EP02791318A patent/EP1455858A4/en not_active Withdrawn
- 2002-11-25 CA CA2467645A patent/CA2467645C/en not_active Expired - Lifetime
- 2002-11-25 MX MXPA04004948A patent/MXPA04004948A/es active IP Right Grant
- 2002-11-25 IL IL16208302A patent/IL162083A0/xx unknown
- 2002-11-25 ME MEP-2008-80A patent/ME00015B/me unknown
- 2002-11-25 WO PCT/US2002/037878 patent/WO2003045466A2/en active Application Filing
- 2002-11-25 JP JP2003546965A patent/JP4458240B2/ja not_active Expired - Lifetime
- 2002-11-25 KR KR10-2004-7007931A patent/KR20040054803A/ko active IP Right Grant
- 2002-11-25 PL PL02371760A patent/PL371760A1/xx unknown
- 2002-11-25 HU HU0600436A patent/HUP0600436A3/hu unknown
- 2002-11-25 KR KR1020107019474A patent/KR20100102745A/ko not_active Application Discontinuation
- 2002-11-25 NZ NZ533029A patent/NZ533029A/en not_active IP Right Cessation
- 2002-11-25 RS YU46204A patent/RS46204A/sr unknown
- 2002-11-25 EA EA200400712A patent/EA007594B1/ru not_active IP Right Cessation
- 2002-11-25 UA UA20040605026A patent/UA81235C2/uk unknown
- 2002-11-25 BR BR0215098-0A patent/BR0215098A/pt not_active IP Right Cessation
- 2002-11-26 UY UY27550A patent/UY27550A1/es not_active Application Discontinuation
- 2002-11-26 TW TW091134325A patent/TWI262794B/zh not_active IP Right Cessation
- 2002-11-26 MY MYPI20024411A patent/MY140404A/en unknown
- 2002-11-26 AR ARP020104542A patent/AR037437A1/es unknown
2004
- 2004-05-20 IL IL162083A patent/IL162083A/en not_active IP Right Cessation
- 2004-05-21 IS IS7275A patent/IS7275A/is unknown
- 2004-05-24 ZA ZA2004/04024A patent/ZA200404024B/en unknown
- 2004-05-26 EC EC2004005123F patent/ECSDI045123S/es unknown
- 2004-05-26 EC EC2004005123A patent/ECSP045123A/es unknown
- 2004-06-03 CO CO04052140A patent/CO5580795A2/es not_active Application Discontinuation
- 2004-06-04 HR HRP20040502 patent/HRP20040502A2/hr not_active Application Discontinuation
- 2004-06-25 NO NO20042693A patent/NO331700B1/no not_active IP Right Cessation
2006
- 2006-06-23 US US11/426,283 patent/US20060257390A1/en not_active Abandoned
- 2006-06-23 US US11/426,263 patent/US7829082B2/en not_active Expired - Lifetime
2008
- 2008-07-15 AU AU2008203131A patent/AU2008203131A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0600436A2 (en)	2006-09-28
NO20042693L (no)	2004-08-25
JP2005510302A (ja)	2005-04-21
UA81235C2 (en)	2007-12-25
TW200303743A (en)	2003-09-16
KR20100102745A (ko)	2010-09-24
US7829082B2 (en)	2010-11-09
WO2003045466A2 (en)	2003-06-05
EA200400712A1 (ru)	2005-06-30
UY27550A1 (es)	2003-06-30
HRP20040502A2 (en)	2004-12-31
CN1617738A (zh)	2005-05-18
CO5580795A2 (es)	2005-11-30
CN100478027C (zh)	2009-04-15
BR0215098A (pt)	2004-12-14
ECSDI045123S (es)	2004-07-23
HUP0600436A3 (en)	2010-12-28
MY140404A (en)	2009-12-31
EA007594B1 (ru)	2006-12-29
AU2008203131A1 (en)	2008-08-07
MXPA04004948A (es)	2004-08-11
IS7275A (is)	2004-05-21
CA2467645A1 (en)	2003-06-05
EP1455858A4 (en)	2006-02-15
IL162083A (en)	2012-12-31
ZA200404024B (en)	2005-07-27
ECSP045123A (es)	2004-07-23
IL162083A0 (en)	2005-11-20
WO2003045466A3 (en)	2003-10-09
JP4458240B2 (ja)	2010-04-28
AR037437A1 (es)	2004-11-10
NZ533029A (en)	2006-05-26
EP1455858A2 (en)	2004-09-15
AU2002365408A1 (en)	2003-06-10
PL371760A1 (en)	2005-06-27
US20060246050A1 (en)	2006-11-02
TWI262794B (en)	2006-10-01
CA2467645C (en)	2017-01-17
MEP8008A (xx)	2010-02-10
US20030206906A1 (en)	2003-11-06
AU2002365408B2 (en)	2008-04-24
RS46204A (en)	2006-10-27
US20060257390A1 (en)	2006-11-16
KR20040054803A (ko)	2004-06-25
ME00015B (me)	2010-06-10

Publication	Publication Date	Title
US7829082B2 (en)	2010-11-09	Catheter composition and uses thereof
US10350334B2 (en)	2019-07-16	Catheter locking solution having antimicrobial and anticoagulation properties
RU2734929C2 (ru)	2020-10-26	Раствор замка катетера и терапия с применением замка катетера
US6187768B1 (en)	2001-02-13	Kit for flushing medical devices and method of preparation
US6350251B1 (en)	2002-02-26	Biocidal locks
Kingston et al.	1986	Self-disinfecting plastics for intravenous catheters and prosthetic inserts
JP5379192B2 (ja)	2013-12-25	殺生物剤ロック
JP5143982B2 (ja)	2013-02-13	殺生物剤ロック
Zeckel et al.	2020	Vancomycin: A clinical overview
Bergeron et al.	1978	Influence of constant infusion versus bolus injections of antibiotics on in vivo synergy
Weck et al.	2005	Alteplase as a catheter locking solution: in vitro evaluation of biochemical stability and antimicrobial properties
Duch-Samper et al.	1996	Anterior chamber contamination following uncomplicated cataract surgery: comparative results using intravenous imipenem
Lentz et al.	2011	In vitro stability and compatibility of tenecteplase in central venous access devices
RU2783927C2 (ru)	2022-11-22	Раствор замка катетера и терапия с применением замка катетера
福島修司 et al.	1987	Pharmacokinetic studies of cefoperazone after bolus injection in patients with benign prostatic hypertrophy.

Legal Events

Date	Code	Title	Description
2014-06-23	MM1K	Lapsed by not paying the annual fees